Use of distinct anti‐hypertensive drugs and risk for COVID‐19 among hypertensive people: A population‐based cohort study in Southern Catalonia, Spain
| Autor: | Josep Basora-Gallisà, Angel Vila-Rovira, Ferran Bejarano-Romero, Frederic Gomez-Bertomeu, Eva Satue-Gracia, Olga Ochoa-Gondar, Cristina Torrente-Fraga, Angel Vila-Corcoles, Dolors Rovira-Veciana, Imma Hospital-Guardiola, Cinta de Diego-Cabanes |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Endocrinology Diabetes and Metabolism Adrenergic beta-Antagonists Population Angiotensin-Converting Enzyme Inhibitors Angiotensin II Receptor Blockers Comorbidity 030204 cardiovascular system & hematology Renin-Angiotensin System Angiotensin Receptor Antagonists 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Outcome Assessment Health Care Internal Medicine Humans Medicine 030212 general & internal medicine Diuretics education Antihypertensive Agents Aged Retrospective Studies Aged 80 and over Covid‐19 education.field_of_study SARS-CoV-2 Proportional hazards model business.industry Incidence Incidence (epidemiology) Hazard ratio COVID-19 Retrospective cohort study Middle Aged Calcium Channel Blockers Spain Case-Control Studies Hypertension Ambulatory Female Cardiology and Cardiovascular Medicine business |
| Zdroj: | J Clin Hypertens (Greenwich) The Journal of Clinical Hypertension |
| ISSN: | 1751-7176 1524-6175 |
| Popis: | The use of some anti‐hypertensive drugs in the current COVID‐19 pandemic has become controversial. This study investigated possible relationships between anti‐hypertensive medications use and COVID‐19 infection risk in the ambulatory hypertensive population. This is a population‐based retrospective cohort study involving 34 936 hypertensive adults >50 years in Tarragona (Southern Catalonia, Spain) who were retrospectively followed through pandemic period (from 01/03/2020 to 30/04/2020). Two data sets including demographic/clinical characteristics (comorbidities and cardiovascular medications use) and laboratory PCR codes for COVID‐19 were linked to construct an anonymized research database. Cox regression was used to calculate multivariable hazard ratios (HRs) and estimate the risk of suffering COVID‐19 infection. Across study period, 205 PCR‐confirmed COVID‐19 cases were observed, which means an overall incidence of 586.8 cases per 100 000 persons‐period. In multivariable analyses, only age (HR: 1.03; 95% CI: 1.02‐1.05; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|